Showing 2171-2180 of 4063 results for "".
- Prism Vision Group Announces Launch of New Brandhttps://modernod.com/news/prism-vision-group-announces-launch-of-new-brand/2476726/Prism Vision Group, an ophthalmology administrative services care provider organization, was officially launched. The new entity is led by Steven Madreperla, MD, PhD, a practicing ophthalmologist and one of the founding partners of NJRetina, a specialty retina practice with roots that reac
- Alcon Launches New Dailies Colors Contact Lenseshttps://modernod.com/news/alcon-launches-new-dailies-colors-contact-lenses/2476702/Alcon officially announced the launch of new Dailies Colors contact lenses—daily disposable contact lenses that combine eye color enhancement with the convenience of a daily wear, according to a company news release. The new line features four colors—Mystic Blue, Mystic Gray, Mystic Hazel and Mys
- Alcon Debuts as Independent, Publicly Traded Companyhttps://modernod.com/news/alcon-debuts-as-independent-publicly-traded-company/2476453/After 8 years under Novartis ownership, Alcon is officially an independent, publicly traded company. On Tuesday, Alcon completed its separation from Novartis and its shares begin trading on the SIX Swiss Exchange and New York Stock Exchange under the symbol “ALC.” American depositary recei
- Carl Zeiss Meditec Completes Acquisition of IanTECHhttps://modernod.com/news/carl-zeiss-meditec-completes-acquisition-of-iantech/2476242/Carl Zeiss Meditec has officially completed its acquisition of IanTECH, a privately held company focused on technology solutions for micro-interventional cataract surgery headquartered in Reno, Nevada. IanTECH is the maker of the miLOOP Lens Fragmentation Device, which is the first in a li
- The Vision Council Urges Commerce Department to Exclude Optical Products from Potential Tariffshttps://modernod.com/news/the-vision-council-urges-commerce-department-to-exclude-optical-products-from-potential-tariffs/2484295/The Vision Council has submitted formal comments to the US Department of Commerce opposing potential new tariffs that could affect essential optical products and equipment. The comments respond to two ongoing Section 2
- FDA Approves Neurotech's Encelto as First and Only FDA-Approved Treatment for MacTelhttps://modernod.com/news/fda-approves-neurotechs-encelto-as-first-and-only-fda-approved-treatment-for-mactel/2482690/Neurotech Pharmaceuticals announced that the FDA has approved Encelto (revakinagene taroretcel-lwey) for the treatment of Macular Telangiectasia type 2 (MacTel). MacTel is a neurodegenerative disease of the retina in adults that causes progressive and irreversible vision
- Roche Stops Clinical Development of Oral Drug Candidate for Diabetic Retinopathyhttps://modernod.com/news/roche-stops-clinical-development-of-oral-drug-candidate-for-diabetic-retinopathy/2481902/Roche has decided to stop development of vicasinabin, an oral drug cadidate being evaluated for non-proliferative diabetic retinopathy, after completing phase 2 trials, according to a FiercePharma
- Kala Pharmaceuticals Announces Commercial Availability of Eysuvis for the Treatment of Dry Eye Diseasehttps://modernod.com/news/kala-pharmaceuticals-announces-commercial-availability-of-eysuvis-for-the-treatment-of-dry-eye-disease/2478729/Kala Pharmaceuticals announced the launch of Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to 2 weeks) treatment of the signs and symptoms of dry eye disease. Eysuvis is now available in national and
- TearSolutions Announces Results From Primary Sjögren’s Syndrome Trial and Appoints Anil Asrani President and CEOhttps://modernod.com/news/tearsolutions-announces-results-from-primary-sjocc88grens-syndrome-trial-and-appoints-anil-asrani-president-and-ceo/2478369/TearSolutions announced the completion and preliminary outcomes of a phase 1/2 trial of Lacripep in Primary Sjögren’s Syndrome (PSS) patients. The trial was designed to test proof of concept and optimize the design f
- Micro Labs USA Launches Two New Glaucoma Drugshttps://modernod.com/news/new-products-launched-by-micro-labs-usa-inc/2478327/Micro Labs USA is launching two products for the treatment of glaucoma in the United States: Dorzolamide 2% and Dorzolamide-Timolol 22.3-6.8 mg/mL. Micro Labs USA said there are additional ophthalmic products under developm